Stuart Randle
Chairman at BEACON ROOFING SUPPLY, INC.
Net worth: 4 M $ as of 2024-04-29
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Jeffrey Hackman | M | 62 |
Comera Life Sciences, Inc.
Comera Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Comera Life Sciences Holdings, Inc., Comera Life Sciences, Inc. is a company that has developed a technology platform to transform the formulation of biotherapeutics for the benefit of patients. The company is based in Woburn, MA. Reform Biologics, a subsidiary of Comera Life Sciences, offers formulation development collaborations and product-specific licenses for a broad spectrum of protein-based therapeutics. The company's patented technology can extend product life-cycles, enable alternative dosing, and improve manufacturing efficiency for biopharmaceutical partners. Reform Biologics creates gentler therapies for fragile patients, including pediatric patients, by using their proprietary technology to transform intravenous drugs into subcutaneous injections, to reduce adverse reactions, and to improve drug stability. The company's goal is to enhance comfort, convenience, safety, and compliance so that patients living with debilitating diseases can experience a better life while treating their medical conditions. The company was founded by David S. Soane, Zachariah Jonasson, and Jeffrey S Hackman has been the CEO of the company since 2021. Comera Life Sciences was acquired by OTR Acquisition Corp. on May 20, 2022 for $156.08 million. | 3 years |
Liam Kelly | M | 57 | 15 years | |
Kirsten Flowers | F | 49 |
ReForm Biologics LLC
ReForm Biologics LLC BiotechnologyHealth Technology ReForm Biologics LLC develops formulation technologies for biotherapeutics molecules. It provides technologies that include Viscosity-reducing excipients, Stability-enhancing excipients, and Surfactant-replacing excipients. The company was founded by David S. Soane and Zachariah Jonasson and is headquartered in Cambridge, MA.
Comera Life Sciences, Inc.
Comera Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Comera Life Sciences Holdings, Inc., Comera Life Sciences, Inc. is a company that has developed a technology platform to transform the formulation of biotherapeutics for the benefit of patients. The company is based in Woburn, MA. Reform Biologics, a subsidiary of Comera Life Sciences, offers formulation development collaborations and product-specific licenses for a broad spectrum of protein-based therapeutics. The company's patented technology can extend product life-cycles, enable alternative dosing, and improve manufacturing efficiency for biopharmaceutical partners. Reform Biologics creates gentler therapies for fragile patients, including pediatric patients, by using their proprietary technology to transform intravenous drugs into subcutaneous injections, to reduce adverse reactions, and to improve drug stability. The company's goal is to enhance comfort, convenience, safety, and compliance so that patients living with debilitating diseases can experience a better life while treating their medical conditions. The company was founded by David S. Soane, Zachariah Jonasson, and Jeffrey S Hackman has been the CEO of the company since 2021. Comera Life Sciences was acquired by OTR Acquisition Corp. on May 20, 2022 for $156.08 million. | 3 years |
James Sherblom | M | 68 |
Comera Life Sciences, Inc.
Comera Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Comera Life Sciences Holdings, Inc., Comera Life Sciences, Inc. is a company that has developed a technology platform to transform the formulation of biotherapeutics for the benefit of patients. The company is based in Woburn, MA. Reform Biologics, a subsidiary of Comera Life Sciences, offers formulation development collaborations and product-specific licenses for a broad spectrum of protein-based therapeutics. The company's patented technology can extend product life-cycles, enable alternative dosing, and improve manufacturing efficiency for biopharmaceutical partners. Reform Biologics creates gentler therapies for fragile patients, including pediatric patients, by using their proprietary technology to transform intravenous drugs into subcutaneous injections, to reduce adverse reactions, and to improve drug stability. The company's goal is to enhance comfort, convenience, safety, and compliance so that patients living with debilitating diseases can experience a better life while treating their medical conditions. The company was founded by David S. Soane, Zachariah Jonasson, and Jeffrey S Hackman has been the CEO of the company since 2021. Comera Life Sciences was acquired by OTR Acquisition Corp. on May 20, 2022 for $156.08 million. | 3 years |
Edward Sullivan | M | - |
ReForm Biologics LLC
ReForm Biologics LLC BiotechnologyHealth Technology ReForm Biologics LLC develops formulation technologies for biotherapeutics molecules. It provides technologies that include Viscosity-reducing excipients, Stability-enhancing excipients, and Surfactant-replacing excipients. The company was founded by David S. Soane and Zachariah Jonasson and is headquartered in Cambridge, MA.
Comera Life Sciences, Inc.
Comera Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Comera Life Sciences Holdings, Inc., Comera Life Sciences, Inc. is a company that has developed a technology platform to transform the formulation of biotherapeutics for the benefit of patients. The company is based in Woburn, MA. Reform Biologics, a subsidiary of Comera Life Sciences, offers formulation development collaborations and product-specific licenses for a broad spectrum of protein-based therapeutics. The company's patented technology can extend product life-cycles, enable alternative dosing, and improve manufacturing efficiency for biopharmaceutical partners. Reform Biologics creates gentler therapies for fragile patients, including pediatric patients, by using their proprietary technology to transform intravenous drugs into subcutaneous injections, to reduce adverse reactions, and to improve drug stability. The company's goal is to enhance comfort, convenience, safety, and compliance so that patients living with debilitating diseases can experience a better life while treating their medical conditions. The company was founded by David S. Soane, Zachariah Jonasson, and Jeffrey S Hackman has been the CEO of the company since 2021. Comera Life Sciences was acquired by OTR Acquisition Corp. on May 20, 2022 for $156.08 million. | 3 years |
Stephen Klasko | M | 70 | 16 years | |
John Yee | M | - |
Comera Life Sciences, Inc.
Comera Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Comera Life Sciences Holdings, Inc., Comera Life Sciences, Inc. is a company that has developed a technology platform to transform the formulation of biotherapeutics for the benefit of patients. The company is based in Woburn, MA. Reform Biologics, a subsidiary of Comera Life Sciences, offers formulation development collaborations and product-specific licenses for a broad spectrum of protein-based therapeutics. The company's patented technology can extend product life-cycles, enable alternative dosing, and improve manufacturing efficiency for biopharmaceutical partners. Reform Biologics creates gentler therapies for fragile patients, including pediatric patients, by using their proprietary technology to transform intravenous drugs into subcutaneous injections, to reduce adverse reactions, and to improve drug stability. The company's goal is to enhance comfort, convenience, safety, and compliance so that patients living with debilitating diseases can experience a better life while treating their medical conditions. The company was founded by David S. Soane, Zachariah Jonasson, and Jeffrey S Hackman has been the CEO of the company since 2021. Comera Life Sciences was acquired by OTR Acquisition Corp. on May 20, 2022 for $156.08 million. | 2 years |
Rima Simson | F | - | - | |
Daniel Logue | M | - | 20 years | |
Julian Francis | M | 57 | 5 years | |
Sirshendu Roopom Banerjee | M | 48 |
Comera Life Sciences, Inc.
Comera Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Comera Life Sciences Holdings, Inc., Comera Life Sciences, Inc. is a company that has developed a technology platform to transform the formulation of biotherapeutics for the benefit of patients. The company is based in Woburn, MA. Reform Biologics, a subsidiary of Comera Life Sciences, offers formulation development collaborations and product-specific licenses for a broad spectrum of protein-based therapeutics. The company's patented technology can extend product life-cycles, enable alternative dosing, and improve manufacturing efficiency for biopharmaceutical partners. Reform Biologics creates gentler therapies for fragile patients, including pediatric patients, by using their proprietary technology to transform intravenous drugs into subcutaneous injections, to reduce adverse reactions, and to improve drug stability. The company's goal is to enhance comfort, convenience, safety, and compliance so that patients living with debilitating diseases can experience a better life while treating their medical conditions. The company was founded by David S. Soane, Zachariah Jonasson, and Jeffrey S Hackman has been the CEO of the company since 2021. Comera Life Sciences was acquired by OTR Acquisition Corp. on May 20, 2022 for $156.08 million. | 3 years |
Michael Campbell | M | - | 2 years | |
Prithvi Gandhi | M | 54 | - | |
Binit Sanghvi | M | - | 3 years | |
Andrew Krakauer | M | 69 | 6 years | |
Robert McLaughlin | M | 67 | 8 years | |
Cameron Hicks | M | 59 | 11 years | |
Jaewon Ryu | M | 50 | 1 years | |
Neal I. Muni | M | - |
Comera Life Sciences, Inc.
Comera Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Comera Life Sciences Holdings, Inc., Comera Life Sciences, Inc. is a company that has developed a technology platform to transform the formulation of biotherapeutics for the benefit of patients. The company is based in Woburn, MA. Reform Biologics, a subsidiary of Comera Life Sciences, offers formulation development collaborations and product-specific licenses for a broad spectrum of protein-based therapeutics. The company's patented technology can extend product life-cycles, enable alternative dosing, and improve manufacturing efficiency for biopharmaceutical partners. Reform Biologics creates gentler therapies for fragile patients, including pediatric patients, by using their proprietary technology to transform intravenous drugs into subcutaneous injections, to reduce adverse reactions, and to improve drug stability. The company's goal is to enhance comfort, convenience, safety, and compliance so that patients living with debilitating diseases can experience a better life while treating their medical conditions. The company was founded by David S. Soane, Zachariah Jonasson, and Jeffrey S Hackman has been the CEO of the company since 2021. Comera Life Sciences was acquired by OTR Acquisition Corp. on May 20, 2022 for $156.08 million. | - |
Racquel Mason | F | 54 | 1 years | |
Earl Newsome | M | 61 | 3 years | |
Christine Reddy | F | 55 | 3 years | |
Dominik Reterski | M | - | - | |
Neena Patil | F | 49 | 2 years | |
Lawrence Keusch | M | - | - | |
Douglas Young | M | 61 | 10 years | |
Alan Gershenhorn | M | 65 | 9 years | |
Karen T. Boylan | F | 52 | 11 years | |
Neil Novich | M | 69 | 12 years | |
John Heinmiller | M | 69 | 5 years | |
Candace Duncan | F | 70 | 9 years | |
V. Lawlis | M | 72 |
ReForm Biologics LLC
ReForm Biologics LLC BiotechnologyHealth Technology ReForm Biologics LLC develops formulation technologies for biotherapeutics molecules. It provides technologies that include Viscosity-reducing excipients, Stability-enhancing excipients, and Surfactant-replacing excipients. The company was founded by David S. Soane and Zachariah Jonasson and is headquartered in Cambridge, MA.
Comera Life Sciences, Inc.
Comera Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Comera Life Sciences Holdings, Inc., Comera Life Sciences, Inc. is a company that has developed a technology platform to transform the formulation of biotherapeutics for the benefit of patients. The company is based in Woburn, MA. Reform Biologics, a subsidiary of Comera Life Sciences, offers formulation development collaborations and product-specific licenses for a broad spectrum of protein-based therapeutics. The company's patented technology can extend product life-cycles, enable alternative dosing, and improve manufacturing efficiency for biopharmaceutical partners. Reform Biologics creates gentler therapies for fragile patients, including pediatric patients, by using their proprietary technology to transform intravenous drugs into subcutaneous injections, to reduce adverse reactions, and to improve drug stability. The company's goal is to enhance comfort, convenience, safety, and compliance so that patients living with debilitating diseases can experience a better life while treating their medical conditions. The company was founded by David S. Soane, Zachariah Jonasson, and Jeffrey S Hackman has been the CEO of the company since 2021. Comera Life Sciences was acquired by OTR Acquisition Corp. on May 20, 2022 for $156.08 million. | - |
Gretchen Haggerty | F | 68 | 8 years | |
Zachariah Jonasson | M | 52 |
Comera Life Sciences, Inc.
Comera Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Comera Life Sciences Holdings, Inc., Comera Life Sciences, Inc. is a company that has developed a technology platform to transform the formulation of biotherapeutics for the benefit of patients. The company is based in Woburn, MA. Reform Biologics, a subsidiary of Comera Life Sciences, offers formulation development collaborations and product-specific licenses for a broad spectrum of protein-based therapeutics. The company's patented technology can extend product life-cycles, enable alternative dosing, and improve manufacturing efficiency for biopharmaceutical partners. Reform Biologics creates gentler therapies for fragile patients, including pediatric patients, by using their proprietary technology to transform intravenous drugs into subcutaneous injections, to reduce adverse reactions, and to improve drug stability. The company's goal is to enhance comfort, convenience, safety, and compliance so that patients living with debilitating diseases can experience a better life while treating their medical conditions. The company was founded by David S. Soane, Zachariah Jonasson, and Jeffrey S Hackman has been the CEO of the company since 2021. Comera Life Sciences was acquired by OTR Acquisition Corp. on May 20, 2022 for $156.08 million. | - |
Barbara Finck | M | 77 |
Comera Life Sciences, Inc.
Comera Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Comera Life Sciences Holdings, Inc., Comera Life Sciences, Inc. is a company that has developed a technology platform to transform the formulation of biotherapeutics for the benefit of patients. The company is based in Woburn, MA. Reform Biologics, a subsidiary of Comera Life Sciences, offers formulation development collaborations and product-specific licenses for a broad spectrum of protein-based therapeutics. The company's patented technology can extend product life-cycles, enable alternative dosing, and improve manufacturing efficiency for biopharmaceutical partners. Reform Biologics creates gentler therapies for fragile patients, including pediatric patients, by using their proprietary technology to transform intravenous drugs into subcutaneous injections, to reduce adverse reactions, and to improve drug stability. The company's goal is to enhance comfort, convenience, safety, and compliance so that patients living with debilitating diseases can experience a better life while treating their medical conditions. The company was founded by David S. Soane, Zachariah Jonasson, and Jeffrey S Hackman has been the CEO of the company since 2021. Comera Life Sciences was acquired by OTR Acquisition Corp. on May 20, 2022 for $156.08 million. | - |
Melanie Housey Hart | F | 51 | 2 years | |
Barbara Fast | F | 70 | 6 years | |
Michael Kryukov | M | - | 17 years | |
Dan Worley | M | - | - | |
Matt Tomkin | M | - | 9 years | |
Jamie Samide | M | - | - | |
Howard Cyr | M | - | 6 years | |
Jason Taylor | M | 52 | - | |
Marie Hendrixson | F | - | 15 years | |
Stephen Balogun | M | - | - | |
Michelle Fox | F | - | 11 years | |
John Deren | M | - | 11 years | |
Timothy Duffy | M | - | 12 years | |
Jay White | M | - | 3 years | |
Greg Bloom | M | - | 42 years | |
C. Best | M | 52 | 24 years | |
Michael K. Durkin | M | - |
Cotting School
| - |
John P. Massarelli | M | - | 18 years | |
Gregg W. Winter | M | 59 | - | |
James Winters | M | - | 6 years | |
Thomas Powell | M | 62 | 13 years | |
Dorothy Clarke | F | 59 | 1 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Michael D. Dale | M | 64 | 2 years | |
William McVicar | M | 66 |
Flex Pharma, Inc.
Flex Pharma, Inc. Pharmaceuticals: MajorHealth Technology Flex Pharma, Inc. operates as a clinical-stage biotechnology company. It operates through the Consumer Operations and Drug Development segments. The Consumer Operations segment includes HOTSHOT product and consumer operations. The Drug Development segment engages in the development of innovative and proprietary drug products to treat muscle cramps and spasms associated with severe neurological conditions. The company was founded by Rod MacKinnon, Bruce Bean, Christoph Westphal, Rich Aldrich, Michelle Dipp, and Jennifer M. Cermak in February 2014 and is headquartered in Boston, MA. | 2 years |
Thomas D. Schmitz | M | 56 | 16 years | |
Benson Smith | M | 76 | 15 years | |
Christoph Westphal | M | 56 |
Flex Pharma, Inc.
Flex Pharma, Inc. Pharmaceuticals: MajorHealth Technology Flex Pharma, Inc. operates as a clinical-stage biotechnology company. It operates through the Consumer Operations and Drug Development segments. The Consumer Operations segment includes HOTSHOT product and consumer operations. The Drug Development segment engages in the development of innovative and proprietary drug products to treat muscle cramps and spasms associated with severe neurological conditions. The company was founded by Rod MacKinnon, Bruce Bean, Christoph Westphal, Rich Aldrich, Michelle Dipp, and Jennifer M. Cermak in February 2014 and is headquartered in Boston, MA. | 4 years |
David R. Grace | M | 64 | 26 years | |
Laurence G. Miller | M | 69 | 10 years | |
Robert Crane | M | 65 | 11 years | |
John McCabe | M | 55 |
Flex Pharma, Inc.
Flex Pharma, Inc. Pharmaceuticals: MajorHealth Technology Flex Pharma, Inc. operates as a clinical-stage biotechnology company. It operates through the Consumer Operations and Drug Development segments. The Consumer Operations segment includes HOTSHOT product and consumer operations. The Drug Development segment engages in the development of innovative and proprietary drug products to treat muscle cramps and spasms associated with severe neurological conditions. The company was founded by Rod MacKinnon, Bruce Bean, Christoph Westphal, Rich Aldrich, Michelle Dipp, and Jennifer M. Cermak in February 2014 and is headquartered in Boston, MA. | 5 years |
Paul M. Isabella | M | 68 | 12 years | |
Michael M. Selzer | M | 71 |
Optobionics Corp.
Optobionics Corp. Electronic ComponentsElectronic Technology Optobionics Corp. develops artificial retina and related devices to restore vision for individuals afflicted with retinitis pigmentosa, age-related macular degeneration, and other outer retinal diseases that can lead to blindness. It was founded by Alan Y. Chow and Vincent Y. Chow in 1990. The company is headquartered in Naperville, IL. | 4 years |
Philip Knisely | M | 69 | 9 years | |
Nathan Sleeper | M | 50 | 7 years | |
Daniel Moore | M | 63 | 6 years | |
Jack Edward Meyer | M | 80 | - | |
C. Eric Swank | M | 55 | 17 years | |
Jeffrey P. Black | M | 63 | 11 years | |
Rick C. Welker | M | - | 9 years | |
Andrew Levine | M | - | 11 years | |
Eric Boutin | M | - |
Flex Pharma, Inc.
Flex Pharma, Inc. Pharmaceuticals: MajorHealth Technology Flex Pharma, Inc. operates as a clinical-stage biotechnology company. It operates through the Consumer Operations and Drug Development segments. The Consumer Operations segment includes HOTSHOT product and consumer operations. The Drug Development segment engages in the development of innovative and proprietary drug products to treat muscle cramps and spasms associated with severe neurological conditions. The company was founded by Rod MacKinnon, Bruce Bean, Christoph Westphal, Rich Aldrich, Michelle Dipp, and Jennifer M. Cermak in February 2014 and is headquartered in Boston, MA. | 1 years |
Robert Hadfield | M | 46 |
Flex Pharma, Inc.
Flex Pharma, Inc. Pharmaceuticals: MajorHealth Technology Flex Pharma, Inc. operates as a clinical-stage biotechnology company. It operates through the Consumer Operations and Drug Development segments. The Consumer Operations segment includes HOTSHOT product and consumer operations. The Drug Development segment engages in the development of innovative and proprietary drug products to treat muscle cramps and spasms associated with severe neurological conditions. The company was founded by Rod MacKinnon, Bruce Bean, Christoph Westphal, Rich Aldrich, Michelle Dipp, and Jennifer M. Cermak in February 2014 and is headquartered in Boston, MA. | 3 years |
William Wexler | M | 65 | 2 years | |
Paul S. Evans | M | 61 |
Specialized Health Products International, Inc.
Specialized Health Products International, Inc. Medical SpecialtiesHealth Technology Specialized Health Products International, Inc. develops, manufactures, and markets proprietary disposable medical devices for clinician and patient safety. Its products include LiftLoc, PowerLoc, and MiniLoc Safety Infusion Set, SecureLoc Safety Introducer Needle, SafeStep Huber Needle Set, and Monoject Bone Marrow Biospy Needles. The company was founded in 1993 and is headquartered in Bountiful, UT. | 8 years |
James Wilson | M | - | - | |
James W. Zug | M | 83 | 10 years | |
Joseph Nowicki | M | 62 | 7 years | |
Patricia C. Barron | F | 81 | 19 years | |
Jeffrey Capello | M | 69 |
Flex Pharma, Inc.
Flex Pharma, Inc. Pharmaceuticals: MajorHealth Technology Flex Pharma, Inc. operates as a clinical-stage biotechnology company. It operates through the Consumer Operations and Drug Development segments. The Consumer Operations segment includes HOTSHOT product and consumer operations. The Drug Development segment engages in the development of innovative and proprietary drug products to treat muscle cramps and spasms associated with severe neurological conditions. The company was founded by Rod MacKinnon, Bruce Bean, Christoph Westphal, Rich Aldrich, Michelle Dipp, and Jennifer M. Cermak in February 2014 and is headquartered in Boston, MA. | 3 years |
Jeffrey Graves | M | 62 | 10 years | |
Carl Berquist | M | 73 | - | |
Keith Merrell | M | 78 |
Specialized Health Products International, Inc.
Specialized Health Products International, Inc. Medical SpecialtiesHealth Technology Specialized Health Products International, Inc. develops, manufactures, and markets proprietary disposable medical devices for clinician and patient safety. Its products include LiftLoc, PowerLoc, and MiniLoc Safety Infusion Set, SecureLoc Safety Introducer Needle, SafeStep Huber Needle Set, and Monoject Bone Marrow Biospy Needles. The company was founded in 1993 and is headquartered in Bountiful, UT. | 7 years |
Harold Yoh | M | 63 | 12 years | |
Marc Kozin | M | 62 |
Flex Pharma, Inc.
Flex Pharma, Inc. Pharmaceuticals: MajorHealth Technology Flex Pharma, Inc. operates as a clinical-stage biotechnology company. It operates through the Consumer Operations and Drug Development segments. The Consumer Operations segment includes HOTSHOT product and consumer operations. The Drug Development segment engages in the development of innovative and proprietary drug products to treat muscle cramps and spasms associated with severe neurological conditions. The company was founded by Rod MacKinnon, Bruce Bean, Christoph Westphal, Rich Aldrich, Michelle Dipp, and Jennifer M. Cermak in February 2014 and is headquartered in Boston, MA. | 5 years |
William Roland Cook | M | 80 | 19 years | |
George Babich | M | 72 | 18 years | |
Sigismundus W. W. Lubsen | M | 80 | 23 years | |
Timothy Barberich | M | 76 | 10 years | |
Wilson Sexton | M | 86 | 12 years | |
Peter M. Gotsch | M | 59 | 20 years | |
James J. Gaffney | M | 82 | 12 years | |
Richard Packer | M | 66 | - | |
Jacob Elguicze | M | 51 | 15 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 99 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Stuart Randle
- Personal Network